In the European Union (EU), Orphan designation, or Orphan Medicinal Product designation, is granted to drugs or biologics intending to treat, diagnose, or prevent a rare, chronically debilitating, or…
On April 6, 2022, biotechnology company Dialectic Therapeutics announced via press release that its therapeutic candidate DT2216, designed for relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) or peripheral T-cell…
Just about one month ago, pharmaceutical company Secura Bio, Inc. ("Secura") shared that the company completed enrollment for the Phase 2 PRIMO clinical trial. Altogether, 101 patients enrolled. The…
While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…
According to a story from globenewswire.com, the pharmaceutical company Portola Pharmaceuticals recently announced that its investigational product cerdulatinib has earned Orphan Drug designation from the US Food and Drug Administration…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
